BERLIN -- The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in different ...

Alphamab Oncology (stock code: 9966.HK) announced that two latest clinical data on biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 for the treatment of primary platinum-refractory ...

Gedatolisib combined with fulvestrant, with or without palbociclib, significantly improved PFS in HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. The triplet regimen reduced ...

Lilly's Verzenio prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment: Indianapolis Monday, October 20, 2025, 12:00 Hrs [IST] Eli Lilly and ...

“DESTINY-Breast11 results support T-DXd [plus] THP as a more effective and less toxic neoadjuvant treatment compared with ddAC-THP, and it may become the preferred regimen for patients with high-risk, ...

Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress ...

These Phase III results could enhance uptake of Eli Lilly's Verzenio alongside ET in the adjuvant breast cancer setting, if ...

AstraZeneca drew some retail investor attention early Monday after the pharma major reported that its cancer therapy Enhertu, developed with Daiichi Sankyo, achieved the highest pathologic complete ...

AstraZeneca Plc and Daiichi Sankyo Co. are challenging Gilead Sciences Inc. for dominance in one of the toughest-to-treat breast cancers, with new data from Europe’s biggest oncology meeting signaling ...

Alongside Enhertu, Daiichi and AstraZeneca's Datroway also showed a 43% reduction in risk of progression or death, marking continued progress in breast cancer treatment. The survival benefit was seen ...

After a median follow-up of 18.9 months, the median PFS was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio (HR), 0.49; 95% confidence interval (CI), 0.39 to ...